Targeted Therapy for Melanomas Without BRAF V600 Mutations

被引：0
作者：
Christian Menzer
Jessica C. Hassel
机构：
[1] University Hospital Heidelberg,Section of DermatoOncology, Department of Dermatology and National Center for Tumor Diseases (NCT)
来源：
Current Treatment Options in Oncology | 2022年 / 23卷
关键词：
Melanoma; MAPK pathway; BRAF; MEK; Targeted therapy; BRAF mutation; V600; Non-V600; Trametinib; Binimetinib; Cobimetinib; C-kit; NRAS; Imatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Modern therapy of advanced melanoma offers effective targeted therapeutic options in the form of BRAF plus MEK inhibition for patients with BRAF V600 mutations. For patients lacking these mutations, checkpoint inhibition remains the only first-line choice for treatment of metastatic disease. However, approximately half of patients do not respond to immunotherapy, requiring effective options for a second-line treatment. Advances in genetic profiling have found other possible target molecules, especially a wide array of rare non-V600 BRAF mutations which may respond to available targeted therapy.
引用
收藏
页码：831 / 842
页数：11
相关论文
共 483 条
  • [11] Pinkel D(2011)Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 1239-3151
  • [12] Bastian BC(2019)Targeted therapy in advanced melanoma with rare BRAF mutations J Clin Oncol 37 3142-3199
  • [13] Cancer Genome Atlas N(2018)Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations Oncogene 37 3183-636
  • [14] Dummer R(2019)Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma N Engl J Med 381 626-238
  • [15] Ascierto PA(2017)Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS Nature 548 234-165
  • [16] Gogas HJ(2019)Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer Clin Cancer Res 25 158-867
  • [17] Long GV(2004)Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 855-39
  • [18] Stroyakovskiy D(2015)Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 30-1079
  • [19] Gogas H(2013)BRAF inhibitor activity in V600R metastatic melanoma Eur J Cancer 49 1073-e1498
  • [20] Menzies AM(2021)Efficacy and safety of trametinib in non-V600 BRAF mutant melanoma: a phase II study Oncologist 26 731-713
12345678910